Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are male or female and older than 50 years of age
- You are willing and able to sign a written consent form to participate
- You are registered with the French social security system
- Your blood sample amounts (for both care and research) can be managed safely based on your body weight
- You have the same type of age-related macular degeneration (AMD — a condition affecting the back of the eye) in both eyes, OR early AMD in one eye and a more advanced form in the other, OR you have no eye disease at all (for the control group)
Who may not be able to join:
- You weigh less than 50 kg (approximately 110 lbs)
- You are an adult under legal guardianship or are unable to give consent for yourself
- You are currently detained or deprived of your liberty
- You are already taking part in another clinical trial at the time of joining this study
- You have one type of advanced AMD (dry/atrophic) in one eye and a different type (wet/exudative) in the other eye
- You have other long-term retinal (back of the eye) conditions beyond AMD
- You are taking medicines that affect your immune system, such as immunosuppressants, chemotherapy, or long-term steroids
- You have a health condition that affects how your immune system works
- You have a history of diabetes
- You have had a specific light-based eye treatment called photodynamic therapy on the eye being studied
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Thibaud Mathis, MD, Service d'Ophtalmologie Hospices Civils de Lyon Hôpital de la Croix Rousse
Phone: 4 26 10 93 22
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Comparison of the survival of human monocytes on ARPE-19 cultures, between the group of patients with atrophic AMD and patient with no retinal pathology (control).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.